Meeting
2021 ASCO Annual Meeting
Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials.
Authors
Thierry Landre
UCOG-HUPSSD-APHP, Paris, France
Thierry Landre , Gregoire Justeau , Jean-baptiste Assié , Kader Chouahnia , Chérifa Taleb , Christos Chouaid , Boris Duchemann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9025)
DOI
10.1200/JCO.2021.39.15_suppl.9025
Abstract #
9025
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.
First Author: Margarita Majem
Poster
2020 ASCO Virtual Scientific Program
Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
First Author: Stephen V. Liu
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.
First Author: Jean-Louis Pujol
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
First Author: Wai Lin Thein